Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Item

http://www.wikidata.org/entity/Q31057145

Q31057145

about

Therapeutic Approach to Adult Fibrotic Lung Diseases Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group.Optimizing quality of life in patients with idiopathic pulmonary fibrosis.Pirfenidone for the treatment of idiopathic pulmonary fibrosis.Role of pirfenidone in the management of pulmonary fibrosis.Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis.The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries Idiopathic pulmonary fibrosis: past, present, future-a review from Talmadge King's ATS 2016 presentation.Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia.Cyclophosphamide for connective tissue disease-associated interstitial lung disease.The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies.Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia.Study the past to divine the future. Confucius' wisdom doesn't work for idiopathic pulmonary fibrosis.Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?Managing patients with interstitial lung disease: Two more pieces of the puzzle.Idiopathic pulmonary fibrosis: pathogenesis and management.Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.Clinical characteristics and factors associated with mortality in idiopathic pulmonary fibrosis: An experience from a tertiary care center in Pakistan.Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials

P2860

Q26741569-A94F9067-113A-4686-B439-D057233C377D Q38598382-1E9C24A6-A633-4402-8E68-45D05CEC2356 Q38634828-C99BB827-6823-48CA-952D-CDA1064A9EC3 Q38833817-737785AC-7CA4-4351-903F-57D2AE5E0BFE Q39013034-B251B740-524B-4651-9F9B-645B097FE30C Q39108878-CD15318C-1C57-4C64-B88F-51F3D9DE16F1 Q39165575-8570AED4-CE61-49B8-92AD-E21BCF31DC51 Q39257627-EE9AC881-8256-4832-B851-6FE8AFF50C4D Q39401141-DC67839F-FE5A-4525-9B56-CF4E281258E6 Q41036251-FEECF818-3849-4DBB-BEB9-1399E1706F0B Q41712176-E27F21D4-B8CB-4924-B645-42AFF2C43EB1 Q42346082-D58FE680-2632-4329-ADEB-A331E2BB6795 Q47191410-67149233-4E11-4C5E-A680-E968D2BF85A0 Q47216089-58774CB8-4B69-48ED-8F12-9822ADF088E5 Q47282447-DF193C16-F974-41FA-BA3D-FF1673271534 Q47791471-17B06403-E297-4557-B3A7-4B60A34E223E Q48149114-24DA6791-DDED-4B33-A537-A0BDB6439A0E Q48218867-057CD728-C5C4-4F3F-8FEF-1FB307D58233 Q48240883-1B711EBD-F434-45A8-8788-1AD116AAE23B Q50326794-BB4C8BC9-091F-48FD-9A3D-E7B8DBD8CBC0 Q51410548-15AD791E-8EF1-4596-8BCF-D6C3B5158BFB Q54337435-723D2D1A-C6C7-4F81-A6C7-E09A347E227E Q55009120-7A243DF6-DF61-44F5-8C15-613B8A96216D Q57071456-81F41736-2DA1-4FB3-BF79-15C857E241A3 Q58803268-45698DA0-9F01-43D0-90AE-B5E474A8FB25

P2860

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Item

http://www.wikidata.org/entity/Q31057145

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu